Related Experiment Video
Updated: May 15, 2026
08:29
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
A modified HSP70 inhibitor shows broad activity as an anticancer agent
Gregor M Balaburski1, Julia I-Ju Leu, Neil Beeharry
1Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA 19104, USA.
Molecular Cancer Research : MCR
|January 11, 2013
Summary
Heat shock protein 70 (HSP70) inhibitors, like PES-Cl, show promise as anticancer drugs. This new compound effectively targets tumor cells, inhibits cancer growth, and extends survival in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Heat shock protein 70 (HSP70) is crucial for protein folding and cell survival.
- HSP70 is overexpressed in cancer cells, making it a therapeutic target.
- HSP70 inhibitors are being developed for cancer treatment.
Purpose of the Study:
- To investigate the binding mechanism of the HSP70 inhibitor 2-phenylethynesulfonamide (PES).
- To identify a more potent derivative of PES for cancer therapy.
- To elucidate the anticancer mechanisms of HSP70 inhibitors.
Main Methods:
- Molecular modeling and in silico docking to identify PES binding sites.
- Structure-activity relationship analysis to develop PES derivatives.
- In vitro assays to assess cytotoxicity, autophagy inhibition, and APC/C activity.
- In vivo studies using mouse models of lymphoma.
Main Results:
- PES binds to the substrate-binding domain of HSP70, requiring its C-terminal helical lid.
- A novel derivative, PES-Cl, demonstrated enhanced cytotoxicity and improved survival in mice.
- HSP70 inhibitors were found to impair anaphase promoting complex/cyclosome (APC/C) activity.
- PES-Cl induced G2-M arrest and genomic instability in cancer cells.
Conclusions:
- PES-Cl is a promising anticancer compound targeting HSP70.
- PES-Cl exhibits multiple mechanisms of action, including APC/C inhibition.
- Further development of PES-Cl warrants investigation for cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...